188 related articles for article (PubMed ID: 38088065)
1. Association of clinical symptoms and cardiometabolic dysregulations in patients with schizophrenia spectrum disorders.
Zhao C; Habtewold TD; Naderi E; Liemburg EJ; ; Bruggeman R; Alizadeh BZ
Eur Psychiatry; 2023 Dec; 67(1):e7. PubMed ID: 38088065
[TBL] [Abstract][Full Text] [Related]
2. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - Baseline and two-years findings from the CHANGE trial.
Storch Jakobsen A; Speyer H; Nørgaard HCB; Hjorthøj C; Krogh J; Mors O; Nordentoft M
Schizophr Res; 2018 Sep; 199():96-102. PubMed ID: 29501386
[TBL] [Abstract][Full Text] [Related]
3. Polygenic risk score for schizophrenia was not associated with glycemic level (HbA1c) in patients with non-affective psychosis: Genetic Risk and Outcome of Psychosis (GROUP) cohort study.
Habtewold TD; Islam MA; Liemburg EJ; ; Bruggeman R; Alizadeh BZ
J Psychosom Res; 2020 May; 132():109968. PubMed ID: 32169752
[TBL] [Abstract][Full Text] [Related]
4. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
[TBL] [Abstract][Full Text] [Related]
5. Adverse differences in cardiometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht Study.
de Ritter R; Sep SJS; van der Kallen CJH; Schram MT; Koster A; Kroon AA; van Greevenbroek MMJ; Eussen SJPM; Dagnelie PC; de Jong M; Vos RC; Woodward M; Bots ML; Peters SAE; Stehouwer CDA
BMJ Open Diabetes Res Care; 2019; 7(1):e000787. PubMed ID: 31798903
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial.
Jensen KG; Correll CU; Rudå D; Klauber DG; Stentebjerg-Olesen M; Fagerlund B; Jepsen JRM; Fink-Jensen A; Pagsberg AK
J Clin Psychiatry; 2017; 78(8):e1035-e1046. PubMed ID: 28102978
[TBL] [Abstract][Full Text] [Related]
7. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia.
Lin BD; Pinzón-Espinosa J; Blouzard E; van der Horst MZ; Okhuijsen-Pfeifer C; van Eijk KR; Guloksuz S; Peyrot WJ; Luykx JJ;
JAMA Psychiatry; 2023 Feb; 80(2):181-185. PubMed ID: 36542388
[TBL] [Abstract][Full Text] [Related]
8. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
[TBL] [Abstract][Full Text] [Related]
9. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study.
Galderisi S; De Hert M; Del Prato S; Fagiolini A; Gorwood P; Leucht S; Maggioni AP; Mucci A; Arango C
Eur Psychiatry; 2021 Jan; 64(1):e7. PubMed ID: 33413701
[TBL] [Abstract][Full Text] [Related]
10. Breastfeeding and cardiometabolic markers at age 12: a population-based birth cohort study.
Pluymen LPM; Wijga AH; Gehring U; Koppelman GH; Smit HA; van Rossem L
Int J Obes (Lond); 2019 Aug; 43(8):1568-1577. PubMed ID: 30886238
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the J shaped curve, exploring the association between cardiovascular risk factors and concurrent depressive symptoms in patients with cardiometabolic disease: Findings from a large cross-sectional study.
Jani BD; Cavanagh J; Barry SJ; Der G; Sattar N; Mair FS
BMC Cardiovasc Disord; 2014 Oct; 14():139. PubMed ID: 25352020
[TBL] [Abstract][Full Text] [Related]
12. Outcome of a psychosocial health promotion intervention aimed at improving physical health and reducing alcohol use in patients with schizophrenia and psychotic disorders (MINT).
Westman J; Eberhard J; Gaughran FP; Lundin L; Stenmark R; Edman G; Eriksson SV; Jedenius E; Rydell P; Overgaard K; Abrams D; Greenwood KE; Smith S; Ismail K; Murray R; Ösby U
Schizophr Res; 2019 Jun; 208():138-144. PubMed ID: 30979666
[TBL] [Abstract][Full Text] [Related]
13. Impact of emotion dysregulation and cognitive insight on psychotic and depressive symptoms during the early course of schizophrenia spectrum disorders.
Liu J; Chan TCT; Chong SA; Subramaniam M; Mahendran R
Early Interv Psychiatry; 2020 Dec; 14(6):691-697. PubMed ID: 31692276
[TBL] [Abstract][Full Text] [Related]
14. Childhood trauma and cardiometabolic risk in severe mental disorders: The mediating role of cognitive control.
Lunding SH; Simonsen C; Aas M; Rødevand L; Werner MCF; Laskemoen JF; Hjell G; Ringen PA; Lagerberg TV; Melle I; Andreassen OA; Ueland T; Steen NE
Eur Psychiatry; 2021 Mar; 64(1):e24. PubMed ID: 33775258
[TBL] [Abstract][Full Text] [Related]
15. Examination of Early Childhood Temperament of Shyness and Social Avoidance and Associations With Cardiometabolic Health in Young Adulthood.
Tang A; Fox NA; Slopen N
JAMA Netw Open; 2022 Jan; 5(1):e2144727. PubMed ID: 35084482
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of cardiometabolic biomarkers and depressive symptoms for symptom severity and quality of life in patients with psychotic disorders.
Perez CSH; Ciufolini S; Sood PG; Krivoy A; Young AH; Murray RM; Ismail K; Atakan Z; Greenwood K; Smith S; Gaughran F; Juruena MF
J Affect Disord; 2022 Feb; 298(Pt A):95-103. PubMed ID: 34699852
[TBL] [Abstract][Full Text] [Related]
17. Cardiometabolic Risk Factors and Incident Cardiovascular Disease Events in Women vs Men With Type 1 Diabetes.
Braffett BH; Bebu I; El Ghormli L; Cowie CC; Sivitz WI; Pop-Busui R; Larkin ME; Gubitosi-Klug RA; Nathan DM; Lachin JM; Dagogo-Jack S;
JAMA Netw Open; 2022 Sep; 5(9):e2230710. PubMed ID: 36074461
[TBL] [Abstract][Full Text] [Related]
18. Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2018; 18(5):1-141. PubMed ID: 30443277
[TBL] [Abstract][Full Text] [Related]
19. Depressive symptoms and glycated hemoglobin A1c: a reciprocal relationship in a prospective cohort study.
Schmitz N; Deschênes S; Burns R; Smith KJ
Psychol Med; 2016 Apr; 46(5):945-55. PubMed ID: 26620309
[TBL] [Abstract][Full Text] [Related]
20. Metabolic disturbances, hemoglobin A1c, and social cognition impairment in Schizophrenia spectrum disorders.
Tang SX; Oliver LD; Hänsel K; DeRosse P; John M; Khairullah A; Gold JM; Buchanan RW; Voineskos A; Malhotra AK
Transl Psychiatry; 2022 Jun; 12(1):233. PubMed ID: 35668078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
